ArticleEpileptic disorders : international epilepsy journal with videotape2026
Differences in mRNA expression of neuroinflammation-related genes in the temporal lobe of patients with drug-resistant focal epilepsy.
Article in Epileptic disorders : international epilepsy journal with videotape, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differences in mRNA expression of neuroinflammation-related genes in the temporal lobe of patients with drug-resistant focal epilepsy.Epileptic disorders : international epilepsy journal with videotape · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesApproximately one-third of epilepsy patients will not achieve seizure freedom with current antiseizure medications, and the identification of novel treatment targets is needed. We characterized alterations in neuroinflammation-related mRNA levels to aid in the identification of possible molecular mediators of DRTLE and discuss the potential for immunomodulatory therapies in this condition.
methodsTemporal lobe samples from DRTLE and postmortem controls without neurological conditions were obtained. RT-qPCR of 60 genes of interest was performed on BioMark Fluidigm custom-made gene expression integrated fluidic circuits (IFC) and cycle threshold values were obtained and analyzed using the
resultsTemporal lobe tissue from 17 DRTLE patients (age: 46.3 ± 12.8 years; female: 35.3%) and 12 controls (age: 56.1 ± 6.1 years; female: 33.3%) were analyzed. Compared to controls, TNF and CCL3 were upregulated 52.7 (p < .0002) and 68.9 (p < .0001)-fold, respectively. C3 was increased by 5.9-fold (p < .0001). IL1B and IL18 were increased 6.4 (p < .0001) and 5.2 (p < .0001) times, respectively. Microglial markers TMEM119 and P2RY12 had a 7.1 (p < .0001) and 5.9 (p < .0001)-fold increase, respectively, with overall lower but significant increases in general mononuclear cell-associated mRNA. There was only low-level or no upregulation of T cell and B cell associated mRNA. No correlation between mRNA alterations and clinical parameters was found. On immunohistochemistry, TMEM119 protein expression was noted in resected brain tissue from DRTLE but was largely absent from controls, consistent with the mRNA results. SIGNIFICANCE: Given the cross-sectional study design, causality cannot be determined. However, this study suggests that proinflammatory mechanisms may play a role in the pathogenesis of the ongoing epileptic state in DRTLE. In particular, complement, inflammasome, and microglial/mononuclear cell-mediated inflammatory processes had the most significant elevations in mRNA, while B and T cell associated mRNA were less altered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.